`
`Todd G. Miller (SBN 163200), miller@fr.com
`Michael A. Amon (SBN 226221), amon@fr.com
`Craig E. Countryman (SBN 244601), countryman@fr.com
`Fish & Richardson P.C.
`12390 El Camino Real
`San Diego, CA 92130
`Phone: 858-678-5070/Fax: 858-678-5099
`
`Frank E. Scherkenbach (SBN 142549), scherkenbach@fr.com
`Fish & Richardson P.C.
`One Marina Park Drive
`Boston, MA 02210-1878
`Phone: 617-542-5070/Fax: 617-542-8906
`
`Jonathan J. Lamberson (SBN 239107), lamberson@fr.com
`Keeley I. Vega (SBN 259928), kvega@fr.com
`Neil A. Warren (SBN 272770), warren@fr.com
`Fish & Richardson P.C.
`500 Arguello St., Ste. 500
`Redwood City, CA 94063
`Telephone: 650-839-5070/Fax: 650-839-5071
`
`Attorneys for Defendant/Counterclaimant NUVASIVE, INC.
`
`
`UNITED STATES DISTRICT COURT
`
`SOUTHERN DISTRICT OF CALIFORNIA
`
`
`WARSAW ORTHOPEDIC, INC.;
`MEDTRONIC SOFAMOR DANEK
`U.S.A., INC.; MEDTRONIC PUERTO
`RICO OPERATIONS CO.; and
`OSTEOTECH, INC.
`
`
`
`
`NUVASIVE, INC.,
`
`
`
`Plaintiffs,
`
`v.
`
`Case No. 3:12-cv-02738 CAB (MDD)
`
`
`NUVASIVE, INC.’S SUPPLEMENTAL
`RESPONSE TO PLAINTIFFS’
`INTERROGATORY NO. 11
`
`
`
`Defendant.
`
`AND RELATED COUNTERCLAIMS.
`
`
`
`
`
`
`
`Case No. 3:12-cv-02738 CAB (MDD)
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`WARSAW2045
`NuVasive, Inc. v. Warsaw Orthopedic, Inc.
`Case IPR2013-00206
`
`Page 1
`
`

`

`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`non-bone, radiolucent construction, that include at least a predefined number
`
`radiopaque markers located in specific areas of the implants, anti-migration features, and
`
`at least one fusion aperture. These features of U.S. Patent Nos. 8,187,334 and 8,361,156,
`
`among others, allow NuVasive’s CoRoent implants, used in NuVasive’s XLIF
`
`procedure, to promote bone growth and fusion when osteoinductive material is placed
`
`in the fusion aperture and the implant implanted in the interbody space of a patient, and
`
`for the implant’s location to be determined relative to the vertebral bodies under
`
`fluoroscopy. This allows surgeons to safely and reproducibly place the CoRoent
`
`implants in the best position within the interbody space, which increases the success of
`
`10
`
`the fusion procedure, and is one of the factors that has contributed to XLIF’s
`
`11
`
`commercial success.
`
`12
`
`The success of the XLIF procedure, the MaXcess line of retractors and the
`
`13
`
`NeuroVision nerve monitoring system (which relate to U.S. Patent Nos. D652,922;
`
`14
`
`8,000,782; 8,005,535; 8,016767; and 8,192,356), and the CoRoent XL line of implants
`
`15
`
`(which relate to U.S. Patent Nos. 8,187,334 and 8,361,156) is exemplified by the
`
`16
`
`phenomenal growth of NuVasive from a small start-up company in 1997 to a company
`
`17
`
`that today provides products, training and support to doctors who perform thousands of
`
`18
`
`XLIF procedures per year. Since its introduction in 2003, more than 100,000 spinal
`
`19
`
`levels have been treated using the XLIF methods and systems, improving the lives of
`
`20
`
`patients, many of whom could not be safely or effectively treated with other surgical
`
`21
`
`approaches and procedures.
`
`22
`
`Equally important, is the widespread adoption of XLIF by surgeons and the
`
`23
`
`positive reviews surgeons give the pioneering XLIF procedure. For example, in the
`
`24
`
`December 15, 2010 issue of SPINE – one of the preeminent peer reviewed journals for
`
`25
`
`spine surgeons – several articles discuss the many advantages of XLIF over conventional
`
`26
`
`surgical approaches for lumbar fusion. Conventional surgical approaches “have been
`
`27
`
`associated with high morbidities that can often offset the benefits of intervention.
`
`28
`
`
`
`
`
`
`
`NuVasive’s Supplemental Response to
`Interrogatory No. 11
`
`47
`
`Case No. 3:12-cv-02738 CAB (MDD)
`
`Page 2
`
`

`

`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`Moreover, the XLIF procedure, and NuVasive’s tools for performing the XLIF
`
`procedure, including the MaXcess Retractor, the CoRoent XL line of implants, and the
`
`NeuroVision nerve monitoring system are being copied by NuVasive’s competitors,
`
`including at least Medtronic, Globus and others.
`
`Additional evidence of the non-obviousness of the claimed inventions can be
`
`found in the skepticism of surgeons at the time of invention as to the safety and efficacy
`
`of traversing the psoas muscle for lateral spinal surgical procedures. Surgeons at that
`
`time generally either avoided the psoas muscle entirely or retracted it during lateral
`
`surgical procedures.
`
`10
`
`Pursuant to Fed. R. Civ. P. 26(e), NuVasive reserves its right to supplement its
`
`11
`
`response to this interrogatory, as necessary, as the evidence develops.
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`
`
`Dated: September 3, 2013
`
`
`FISH & RICHARDSON P.C.
`
`
`
`
`
`
`
`
`
`
`By:
`
`Jonathan J. Lamberson
`
`Attorneys for Defendant/Counterclaimant
`NUVASIVE, INC.
`
`
`
`50920632.doc
`
`
`
`
`
`
`
`NuVasive’s Supplemental Response to
`Interrogatory No. 11
`
`49
`
`Case No. 3:12-cv-02738 CAB (MDD)
`
`Page 3
`
`

`

`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a true and correct copy of the above and
`
`foregoing document has been served on September 3, 2013 to the following individuals
`
`via electronic mail.
`
`
`
`
`
`Luke L. Dauchot, SBN 229829
`Alexander F. MacKinnon, SBN 146883
`Nimalka R. Wickramaseker, SBN 26814
`Sharre Lotfollahi, SBN 258913
`Kirkland & Ellis LLP
`333 South Hope Street
`Los Angeles, CA 90017
`Phone: 213-680-8400
`Fax: 213-680-8500
`Service email: Medtronic-NuVasiveIII@kirkland.com
`Personal emails: ldauchot@kirkland.com;
`nimalka.wickramasekera@kirkland.com;
`alexander.mackinnon@kirkland.com; sharre.lotfollahi@kirkland.com
`
` I declare under penalty of perjury that the foregoing is true and correct.
`
`Executed this 3rd day of September, 2013, at Redwood City, California.
`
`
`
`
`
`
`50920632.doc
`
`
`
`
`Jonathan J. Lamberson
`
`NuVasive’s Objections and Responses to 2nd Set
`of Interrogatories (Nos. 11-13)
`
`
`
`
`50
`
`Case No. 3:12-cv-02738 CAB (MDD)
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`
`
`Page 4
`
`